Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Sponsor: Eidos Therapeutics, a BridgeBio company
Summary
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Official title: An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-07
Completion Date
2030-11
Last Updated
2026-07-29
Healthy Volunteers
No
Conditions
Interventions
Acoramidis (AG10) oral tablet
Study drug is defined as acoramidis 712 mg (equivalent to 800 mg acoramidis hydrochloride) taken orally twice daily for 36 months of open label treatment.
Locations (1)
Washington University in St. Louis
St Louis, Missouri, United States